102
Participants
Start Date
September 20, 2021
Primary Completion Date
August 31, 2025
Study Completion Date
December 31, 2025
ERAS-007
Administered orally
Encorafenib
Administered orally
Cetuximab
Administered via intravenous infusion
Palbociclib
Administered orally
The Johns Hopkins Hospital, Baltimore
Virginia Cancer Specialists, Fairfax
Duke Cancer Institute, Durham
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham
Sarah Cannon Research Institute (Tennessee Oncology), Nashville
Henry Ford Cancer Institute, Detroit
Washington University (Siteman Cancer Center), St Louis
Stephenson Cancer Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
City of Hope, Duarte
University of California Irvine College of Medicine, Orange
UCSF Mount Zion Medical Ctr, San Francisco
University of Washington - Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Erasca, Inc.
INDUSTRY